Loading...

We've got a brand new version of Simply Wall St! Try it out

SynCore BiotechnologyLtd

GTSM:4192
Snowflake Description

Excellent balance sheet with weak fundamentals.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
4192
GTSM
NT$3B
Market Cap
  1. Home
  2. TW
  3. Pharmaceuticals & Biotech
Company description

SynCore Biotechnology Co.,Ltd, a biopharmaceutical company, engages in the research and development, manufacture, and marketing of drugs in the areas of oncology, ophthalmology, dermatology, and infectious diseases in Taiwan and internationally. The last earnings update was 8 days ago. More info.


Add to Portfolio Compare Print
4192 Share Price and Events
7 Day Returns
0%
GTSM:4192
-1.7%
TW Pharmaceuticals
-0.5%
TW Market
1 Year Returns
22.4%
GTSM:4192
16%
TW Pharmaceuticals
17.7%
TW Market
4192 Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
SynCore BiotechnologyLtd (4192) 0% 1.3% 0.3% 22.4% 2.2% -45.6%
TW Pharmaceuticals -1.7% 3.4% 3.5% 16% -10.7% -23.2%
TW Market -0.5% 2.8% 9.1% 17.7% 26.3% 26.1%
1 Year Return vs Industry and Market
  • 4192 outperformed the Pharmaceuticals industry which returned 16% over the past year.
  • 4192 outperformed the Market in Taiwan, Province of China which returned 17.7% over the past year.
Price Volatility
4192
Industry
5yr Volatility vs Market
Related Companies

Sorry, no analysis for SynCore BiotechnologyLtd's competitors could be found in our database.

4192 Value

 Is SynCore BiotechnologyLtd undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for SynCore BiotechnologyLtd. This is due to cash flow or dividend data being unavailable. The share price is NT$30.1.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for SynCore BiotechnologyLtd's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are SynCore BiotechnologyLtd's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
GTSM:4192 PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-09-30) in TWD NT$-4.49
GTSM:4192 Share Price ** GTSM (2019-11-18) in TWD NT$30.1
Taiwan, Province of China Pharmaceuticals Industry PE Ratio Median Figure of 26 Publicly-Listed Pharmaceuticals Companies 22.23x
Taiwan, Province of China Market PE Ratio Median Figure of 1,423 Publicly-Listed Companies 16.59x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of SynCore BiotechnologyLtd.

GTSM:4192 PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= GTSM:4192 Share Price ÷ EPS (both in TWD)

= 30.1 ÷ -4.49

-6.71x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • SynCore BiotechnologyLtd is loss making, we can't compare its value to the TW Pharmaceuticals industry average.
  • SynCore BiotechnologyLtd is loss making, we can't compare the value of its earnings to the Taiwan, Province of China market.
Price based on expected Growth
Does SynCore BiotechnologyLtd's expected growth come at a high price?
Raw Data
GTSM:4192 PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -6.71x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
Taiwan, Province of China Pharmaceuticals Industry PEG Ratio Median Figure of 5 Publicly-Listed Pharmaceuticals Companies 0.89x
Taiwan, Province of China Market PEG Ratio Median Figure of 247 Publicly-Listed Companies 1.07x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for SynCore BiotechnologyLtd, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on SynCore BiotechnologyLtd's assets?
Raw Data
GTSM:4192 PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-09-30) in TWD NT$8.16
GTSM:4192 Share Price * GTSM (2019-11-18) in TWD NT$30.1
Taiwan, Province of China Pharmaceuticals Industry PB Ratio Median Figure of 45 Publicly-Listed Pharmaceuticals Companies 2.17x
Taiwan, Province of China Market PB Ratio Median Figure of 1,936 Publicly-Listed Companies 1.44x
GTSM:4192 PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= GTSM:4192 Share Price ÷ Book Value per Share (both in TWD)

= 30.1 ÷ 8.16

3.69x

* Primary Listing of SynCore BiotechnologyLtd.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • SynCore BiotechnologyLtd is overvalued based on assets compared to the TW Pharmaceuticals industry average.
X
Value checks
We assess SynCore BiotechnologyLtd's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Pharmaceuticals industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Pharmaceuticals industry average (and greater than 0)? (1 check)
  5. SynCore BiotechnologyLtd has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

4192 Future Performance

 How is SynCore BiotechnologyLtd expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as SynCore BiotechnologyLtd has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
11.8%
Expected Pharmaceuticals industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is SynCore BiotechnologyLtd expected to grow at an attractive rate?
  • Unable to compare SynCore BiotechnologyLtd's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare SynCore BiotechnologyLtd's earnings growth to the Taiwan, Province of China market average as no estimate data is available.
  • Unable to compare SynCore BiotechnologyLtd's revenue growth to the Taiwan, Province of China market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
GTSM:4192 Future Growth Rates Data Sources
Data Point Source Value (per year)
Taiwan, Province of China Pharmaceuticals Industry Earnings Growth Rate Market Cap Weighted Average 11.8%
Taiwan, Province of China Pharmaceuticals Industry Revenue Growth Rate Market Cap Weighted Average 20.2%
Taiwan, Province of China Market Earnings Growth Rate Market Cap Weighted Average 11.4%
Taiwan, Province of China Market Revenue Growth Rate Market Cap Weighted Average 8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
GTSM:4192 Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (1 month ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in TWD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
GTSM:4192 Past Financials Data
Date (Data in TWD Millions) Revenue Cash Flow Net Income *
2019-09-30 13 -359 -389
2019-06-30 13 -337 -359
2019-03-31 12 -305 -306
2018-12-31 8 -272 -294
2018-09-30 8 -229 -270
2018-06-30 8 -197 -253
2018-03-31 8 -184 -247
2017-12-31 8 -202 -258
2017-09-30 8 -218 -186
2017-06-30 8 -220 -177
2017-03-31 7 -225 -176
2016-12-31 7 -195 -162

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if SynCore BiotechnologyLtd is high growth as no earnings estimate data is available.
  • Unable to determine if SynCore BiotechnologyLtd is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
GTSM:4192 Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (1 month ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from SynCore BiotechnologyLtd Company Filings, last reported 1 month ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

GTSM:4192 Past Financials Data
Date (Data in TWD Millions) EPS *
2019-09-30 -4.49
2019-06-30 -4.34
2019-03-31 -3.86
2018-12-31 -3.88
2018-09-30 -3.72
2018-06-30 -3.62
2018-03-31 -3.53
2017-12-31 -3.69
2017-09-30 -2.66
2017-06-30 -2.61
2017-03-31 -2.72
2016-12-31 -2.62

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if SynCore BiotechnologyLtd will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Examine SynCore BiotechnologyLtd's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
  2. SynCore BiotechnologyLtd's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Pharmaceuticals & Biotech companies here
  3. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess SynCore BiotechnologyLtd's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Taiwan, Province of China market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Taiwan, Province of China market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
SynCore BiotechnologyLtd has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

4192 Past Performance

  How has SynCore BiotechnologyLtd performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare SynCore BiotechnologyLtd's growth in the last year to its industry (Pharmaceuticals).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • SynCore BiotechnologyLtd does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare SynCore BiotechnologyLtd's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare SynCore BiotechnologyLtd's 1-year growth to the TW Pharmaceuticals industry average as it is not currently profitable.
Earnings and Revenue History
SynCore BiotechnologyLtd's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from SynCore BiotechnologyLtd Company Filings, last reported 1 month ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

GTSM:4192 Past Revenue, Cash Flow and Net Income Data
Date (Data in TWD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-09-30 12.77 -388.62 45.13 361.61
2019-06-30 12.74 -358.65 46.76 328.66
2019-03-31 12.35 -305.75 46.61 275.52
2018-12-31 7.71 -294.13 47.52 257.57
2018-09-30 7.77 -269.54 46.31 228.71
2018-06-30 7.81 -253.01 43.58 216.08
2018-03-31 8.14 -246.86 43.53 212.33
2017-12-31 8.14 -257.99 39.75 224.33
2017-09-30 8.16 -185.95 38.67 228.27
2017-06-30 7.74 -176.95 38.63 219.14
2017-03-31 7.26 -176.48 36.90 222.55
2016-12-31 6.90 -162.24 38.45 208.47
2016-09-30 6.72 -184.64 38.86 178.98
2016-06-30 6.86 -200.63 44.30 190.42
2016-03-31 15.62 -178.75 47.28 167.51
2015-12-31 15.46 -182.16 48.23 169.79
2015-09-30 15.16 -223.23 58.18 203.61
2015-06-30 14.68 -223.04 63.16 195.60
2015-03-31 5.34 -244.29 61.71 209.68
2014-12-31 5.07 -231.20 59.52 200.29
2014-09-30 4.31 -214.36 49.34 168.75
2014-06-30 3.02 -174.01 38.47 139.14
2014-03-31 1.81 -128.74 34.98 97.30
2013-12-31 0.76 -106.23 33.39 75.68
2012-12-31 -72.67 11.66 43.73

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if SynCore BiotechnologyLtd has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if SynCore BiotechnologyLtd has efficiently used its assets last year compared to the TW Pharmaceuticals industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if SynCore BiotechnologyLtd improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess SynCore BiotechnologyLtd's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Pharmaceuticals industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
SynCore BiotechnologyLtd has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

4192 Health

 How is SynCore BiotechnologyLtd's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up SynCore BiotechnologyLtd's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • SynCore BiotechnologyLtd is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • SynCore BiotechnologyLtd's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of SynCore BiotechnologyLtd's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 22.1x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from SynCore BiotechnologyLtd Company Filings, last reported 1 month ago.

GTSM:4192 Past Debt and Equity Data
Date (Data in TWD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-09-30 741.23 30.00 537.87
2019-06-30 521.34 0.00 396.74
2019-03-31 650.22 20.00 380.81
2018-12-31 706.70 0.00 479.29
2018-09-30 836.89 0.00 575.00
2018-06-30 589.51 0.00 329.82
2018-03-31 682.41 20.00 405.88
2017-12-31 720.61 0.00 469.33
2017-09-30 790.82 0.00 520.84
2017-06-30 835.81 0.00 566.83
2017-03-31 895.86 0.00 614.56
2016-12-31 966.36 0.00 718.63
2016-09-30 1,001.29 0.00 619.87
2016-06-30 673.14 0.00 323.87
2016-03-31 756.16 10.00 384.70
2015-12-31 842.81 0.00 444.52
2015-09-30 795.73 0.00 467.83
2015-06-30 919.97 0.00 516.53
2015-03-31 1,055.02 0.00 619.65
2014-12-31 896.73 0.00 722.03
2014-09-30 376.50 0.00 207.42
2014-06-30 483.25 0.00 310.90
2014-03-31 549.36 0.00 416.93
2013-12-31 549.36 0.00 416.93
2012-12-31 221.35 0.00 179.73
  • SynCore BiotechnologyLtd's level of debt (4%) compared to net worth is satisfactory (less than 40%).
  • Unable to establish if SynCore BiotechnologyLtd's debt level has increased without past 5-year debt data.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • SynCore BiotechnologyLtd has sufficient cash runway for 1.5 years based on current free cash flow.
  • SynCore BiotechnologyLtd has sufficient cash runway for 1.2 years if free cash flow continues to grow at historical rates of 21.3% each year.
X
Financial health checks
We assess SynCore BiotechnologyLtd's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. SynCore BiotechnologyLtd has a total score of 5/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

4192 Dividends

 What is SynCore BiotechnologyLtd's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from SynCore BiotechnologyLtd dividends.
If you bought NT$2,000 of SynCore BiotechnologyLtd shares you are expected to receive NT$0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate SynCore BiotechnologyLtd's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate SynCore BiotechnologyLtd's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
GTSM:4192 Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
Taiwan, Province of China Pharmaceuticals Industry Average Dividend Yield Market Cap Weighted Average of 23 Stocks 2.8%
Taiwan, Province of China Market Average Dividend Yield Market Cap Weighted Average of 1323 Stocks 4.1%
Taiwan, Province of China Minimum Threshold Dividend Yield 10th Percentile 1.4%
Taiwan, Province of China Bottom 25% Dividend Yield 25th Percentile 2.6%
Taiwan, Province of China Top 25% Dividend Yield 75th Percentile 5.9%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as SynCore BiotechnologyLtd has not reported any payouts.
  • Unable to verify if SynCore BiotechnologyLtd's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of SynCore BiotechnologyLtd's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as SynCore BiotechnologyLtd has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess SynCore BiotechnologyLtd's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.4%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can SynCore BiotechnologyLtd afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. SynCore BiotechnologyLtd has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

4192 Management

 What is the CEO of SynCore BiotechnologyLtd's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Chih-Wen Lee
COMPENSATION NT$954,000
CEO Bio

Mr. Chih-Wen Lee is Chairman of Syncore Biotechnology Co., Ltd. and serves as its Director since June 09, 2008. Mr. Lee is Chief Executive Officer of SynCore Biotechnology Co.,Ltd. Mr. Lee founded Sinphar Pharmaceutical Co., Ltd. in 1977. He is an active member of the pharmaceutical industry and is well respected. Mr. Lee serves as Director of I-Lan Youngsun Education Foundation, Canadian Aging and Cancer Foundation, and Taiwan Cancer Foundation. Also, he serves as the council member of Society of Chinese Bioscientists in America, Pharmaceutical Division. His experience includes Chairman of Sinphar Pharmaceutical Co., Ltd.; Chairman of ZuniMed Biotech Co., Ltd.; Chairman of Sunetic Biotech Inc; Chairman of Universal Next Technology Inc and Director of Xing-Da Capital Crop. He served as president of Chinese-Canadian Academic and Professional Association, and the co-chairman of Pharmaceutical Market Conference organized by International Chinese Biotechnology Association. Mr. Lee also participates in Taiwanese National Development Assembly Forums and is a committeeman of Drug reviewing Committee of National Science Council. He holds BA, School of Pharmacy from Kaoshiung Medical University.

CEO Compensation
  • Chih-Wen's compensation has been consistent with company performance over the past year, both up more than 20%.
  • Chih-Wen's remuneration is higher than average for companies of similar size in Taiwan, Province of China.
Management Team

Chih-Wen Lee

TITLE
Founder
COMPENSATION
NT$954K

Muh-Hwan Su

TITLE
President
COMPENSATION
NT$4M
TENURE
6.4 yrs
Board of Directors Tenure

Average tenure of the SynCore BiotechnologyLtd board of directors in years:

6
Average Tenure
  • The tenure for the SynCore BiotechnologyLtd board of directors is about average.
Board of Directors

Yi-Ta Lee

TITLE
Deputy Chairman
COMPENSATION
NT$858K
TENURE
5.8 yrs

Chih-Wen Lee

TITLE
Founder
COMPENSATION
NT$954K

Muh-Hwan Su

TITLE
President
COMPENSATION
NT$4M
TENURE
11.4 yrs

Wen-Feng Chen

TITLE
Independent Director
COMPENSATION
NT$194K
TENURE
6 yrs

Hui-Hwa Yang

TITLE
Director
COMPENSATION
NT$138K
TENURE
6 yrs

Whu-Ju Chu

TITLE
Director
COMPENSATION
NT$42K
TENURE
6.4 yrs

Jih-Heng Li

TITLE
Independent Director
COMPENSATION
NT$194K
TENURE
6 yrs

Fu-Hsing Chang

TITLE
Independent Director
COMPENSATION
NT$201K
TENURE
6 yrs

Bo Lai

TITLE
Director
TENURE
1.4 yrs

Shih-Chia Lin

TITLE
Representative Director
TENURE
1.3 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (NT$) Value (NT$)
X
Management checks
We assess SynCore BiotechnologyLtd's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. SynCore BiotechnologyLtd has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

4192 News

Simply Wall St News

4192 Company Info

Description

SynCore Biotechnology Co.,Ltd, a biopharmaceutical company, engages in the research and development, manufacture, and marketing of drugs in the areas of oncology, ophthalmology, dermatology, and infectious diseases in Taiwan and internationally. The company offers SB03-Veregen, an ointment for the treatment of patients with external genital and perianal warts; and distributes cameras under the epiCam name that is used in recording the progress of ophthalmology diseases. It is also involved in the development of SB01, an injectable anti-cancer NCE that is in Phase II clinical trial for the treatment of head and neck cancer; SB02, an anti-cancer NCE, which is in Phase I clinical trial for use in the treatment of stomach cancer; SB04 that is in Phase II/III clinical trial for the treatment of patients with dry age-related macular degeneration; and SB05, a composition of cytostatic drug paclitaxel combined with neutral and positive lipids, which is in Phase III clinical trials for the treatment of patients with triple negative breast cancer and pancreas cancer. The company was founded in 2008 and is headquartered in Yilan, Taiwan. SynCore Biotechnology Co.,Ltd is a subsidiary of Sinphar Pharmaceutical Co., Ltd.

Details
Name: SynCore Biotechnology Co.,Ltd
4192
Exchange: GTSM
Founded: 2008
NT$2,930,746,700
97,367,000
Website: http://www.syncorebio.com
Address: SynCore Biotechnology Co.,Ltd
84 Chung Shan Road,
Chung Shan Village,
Yilan,
269,
Taiwan
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
GTSM 4192 Common Stock Taipei Exchange TW TWD 29. Aug 2013
Number of employees
Current staff
Staff numbers
81
SynCore BiotechnologyLtd employees.
Industry
Pharmaceuticals
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/11/18 15:38
End of day share price update: 2019/11/18 00:00
Last earnings filing: 2019/11/10
Last earnings reported: 2019/09/30
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.